GSK vaccine for older adults granted FDA priority review

France Nouvelles Nouvelles

GSK vaccine for older adults granted FDA priority review
France Dernières Nouvelles,France Actualités
  • 📰 FoxBusiness
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 53%

GSK reported strong third-quarter earnings and raised its forecast for 2022. However worries about Zantac litigation kept investors on edge.

GSK opened 2% higher in U.S. trading Wednesday but closed down 2%. Shares rose after the drugmaker reported financial results that beat Wall Street forecasts and announced the Food and Drug Administration had accepted a biologics license application and granted priority review to its vaccine for respiratory syncytial virus targeted at adults aged 60 years or older.

RSV is a common contagious virus affecting the lungs and breathing passages. It is one of the major remaining infectious diseases for which there is currently no vaccine or specific treatment available for adults. RSV causes over 420,000 hospitalizations each year and 29,000 deaths in adults in industrialized countries. Adults with underlying conditions are more likely to seek medical advice and have higher hospitalisation rates than adults without these conditions.

"Vaccines have stolen the show in GSK’s third quarter update today as the shingles vaccine, Shingrix, saw record sales. The continued roll-out is a key driver of the upgraded guidance for 2022, as are launches for the RSV vaccine," said Derren Nathan, Head of Equity Research at Hargreaves Lansdown.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

FoxBusiness /  🏆 458. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Holiday Hits 2022, Week 1: Hot Toys of 2022Holiday Hits 2022, Week 1: Hot Toys of 2022The Toy Insider’s Laurie Schacht is highlighting some of the hottest toys of 2022.
Lire la suite »

New GSK maintains strong start, but Zantac litigation looms largeNew GSK maintains strong start, but Zantac litigation looms largeGSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division.
Lire la suite »

22 Don’t-Miss Beauty Deals From the Sephora Sale 202222 Don’t-Miss Beauty Deals From the Sephora Sale 2022Now is the time to stock up on soothing skin care, next-gen hot tools, and giftable sets—all at a nearly sitewide discount.
Lire la suite »

Amazon Echo deals for Alexa's birthday hit the lowest prices of 2022Amazon Echo deals for Alexa's birthday hit the lowest prices of 2022Amazon Echo deals are back for Alexa's birthday! Get the Echo Dot, Echo, Echo Buds, Echo Auto, and more at the lowest prices of 2022.
Lire la suite »

A community in photos: Looking back at October 2022 in SaskatoonA community in photos: Looking back at October 2022 in SaskatoonStarPhoenix photographers shot some memorable moments around Saskatoon last month.
Lire la suite »

Mega MAGA: Here's where Trump's influence was strongest in Arizona's 2022 GOP primaryMega MAGA: Here's where Trump's influence was strongest in Arizona's 2022 GOP primaryIn May, President Biden inveighed against what he called the “ultra MAGA” agenda. The azcentral's research identified the places where MAGA is not just popular, but overwhelming. Call it mega MAGA.
Lire la suite »



Render Time: 2025-03-12 17:57:27